The global cryptococcal antigen lateral flow assay test market was valued at around US$ 688.19 Million at the end of 2021. The market is projected to register a 3.73% CAGR and top a valuation of US$ 713.85 Million by 2032.
Growing advantages of cryptococcal antigen lateral flow assay test such as it uses two monoclonal antibodies impregnated into an immunochromatographic test strip to detect (CrAg) cryptococcal antigen and combined strong CrAg reactivity throughout the range of cryptococcal serotypes.
The immunochromotography test technique known as the cryptococcal antigen lateral flow assay is used to determine the capsule polysaccharides antigens of cryptococcus species that are found in cerebrospinal fluid (CSF) and serum.
The diagnosis of cryptococcal fungus at the point of care has undergone revolutionary modifications due to the combined use of immunoassay and chromatography. Through one strip of a lateral flow assay test, the patient is allowing to monitoring of the presence of a fungal infection.
These tests are becoming more and more common throughout the most industrialized countries in North America and Europe as a result of their straightforward operating method in comparison to other assay techniques. Additionally, the great sensitivity and accuracy with the shortest lead time to produce results are opening doors for early stage development products.
| Attributes | Details |
|---|---|
| Cryptococcal Antigen Lateral Flow Assay Test Market Value in 2021 | US$ 688.19 Million |
| Cryptococcal Antigen Lateral Flow Assay Test Market Value in 2032 | US$ 713.85 Million |
| Cryptococcal Antigen Lateral Flow Assay Test Market CAGR (2022 to 2032) | 3.73% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Cryptococcosis neoformans is a fungus that causes Cryptococcosis. Humans may contract the virus by coming into touch with unwashed raw fruit or pigeon droppings. Additionally, contact with an infected person may spread the virus. High risk groups for these diseases include people with diseases that are characterised by lowered immunity, such as HIV infection.
Additionally, increasing prevalence of lower immunity conditions such as HIV infection is supposed to boost the market for cryptococcal antigen lateral flow assay test. For instance, in 2021, according to World Health Organization around 38.4 million people where suffering from HIV, whereas around 1.5 million new cases reported during 2021. In this total almost 6,50,000 individuals died during HIV in 2021.
Moreover, the market for cryptococcal antigen lateral flow assay tests is expected to rise as a result of factors like rising rates of cryptococcal infection, long wait times for test results to come, and the ineffectiveness of other approaches.
The cryptococcal antigen lateral flow assay test market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
Middle East and Africa dominated the regional cryptococcal antigen lateral flow assay tests market due to increased adoption of assays as a result of rapid technological development and innovations for rapid laboratory testing.
In 2019, the WHO recommended countries to adopt a regular HIV testing strategy with three consecutive reactive testing methods for an HIV-positive diagnostic testing to make sure of the quality services as companies operate toward and achieve the UNAIDS 95-95-95 targets. This recommendation was issued in response to changing epidemiology. The guidelines also emphasised the need to phase out obsolete testing technologies, such as western blotting techniques, and to provide dual HIV/syphilis rapid diagnostic tests (RDTs). At that time, compliance with HIV testing policies increased in the WHO African region from 8% in 2014 to 71% in 2021. This factor significantly boosted the market growth in this region.
Principal Consultant
Kestrel Biosciences LIC., Alere, Inc., BioMerieux, Danaher Corporation, Forsite Diagnostics, Merck Millipore, Qiagen, Roche Diagnostics, Hologic (Gen-Probe), and Siemens Healthcare.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 3.73% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Instruments, Test Location, End-User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Spain, Italy, Russia, BENELUX, China, Japan, South Korea, India, Malaysia, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, North Africa, Turkey |
| Key Players | Kestrel Biosciences LIC.; Alere, Inc; BioMerieux; Danaher Corporation; Forsite Diagnostics; Merck Millipore; Qiagen; Roche Diagnostics; Hologic (Gen-Probe); Siemens Healthcare; |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global cryptococcal antigen lateral flow assay test market is anticipated to register a CAGR of 3.73% during the forecast period.
Kestrel Biosciences LIC., Alere, Inc., BioMerieux, Danaher Corporation, Forsite Diagnostics, Merck Millipore, Qiagen, Roche Diagnostics, Hologic (Gen-Probe), and Siemens Healthcare., among others are some prominent cryptococcal antigen lateral flow assay test market players.
Explore Healthcare Insights
View Reports
Cryptococcal Antigen Lateral Flow Assay Test Market
